Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals with Buy Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Milestone Pharmaceuticals with a Buy rating and set a price target of $9.

August 22, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Milestone Pharmaceuticals with a Buy rating and a price target of $9, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $9 by Rodman & Renshaw suggests a positive sentiment towards Milestone Pharmaceuticals. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100